Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ZS Pharma Inc to present data from Phase 3 trial of ZS-9 in late-breaking poster presentation


Friday, 13 Jun 2014 11:00am EDT 

ZS Pharma Inc:Says data from a pivotal Phase 3 trial of ZS-9, its investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial poster.Company's Phase 3 trial, ZS003, assessed safety and efficacy of ZS-9 in treating patients with hyperkalemia, a life-threatening condition that is characterized by higher than normal levels of potassium (K+) in the blood serum.To date, Phase 2 and Phase 3 clinical trials of ZS-9 have demonstrated significant, rapid and sustainable reductions in serum potassium with safety profile similar to placebo.Results demonstrated that both 5g and 10g doses of ZS-9, administered once daily, controlled potassium at normal levels in patients who were hyperkalemic at baseline.Late-Breaking Poster Presentation ZS-9 Achieves and Maintains Normal K+ in Hyperkalemic Patients with Diabetes on RAASi. 

Company Quote

54.78
1.09 +2.03%
4 Sep 2015